[1] Carey I, Gersch J, Wang B, et al. Pre-genomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis Be antigen negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy. Hepatology, 2020,72:42-57.
[2] Otsuka M, Koike K. Should level of HBV RNA be used to determine when patients should stop treatment with nucleos(t)ide analogues. Clin Gastroenterol Hepatol, 2020,18:551-552.
[3] Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol, 2016, 64: S84-S101.
[4] Tu T, Budzinska MA, Vondran FWR, et al. Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles. J Virol, 2018, 92:e02007-17.
[5] Wooddell CI, Yuen MF, Chan HL, et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med, 2017, 9:eaan0241.
[6] Wang J, Yu Y, Li G, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol, 2017,S0168-8278:32261-32264.
[7] Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol, 2016, 65: 700-710.
[8] Wang J, Sheng Q, Ding Y, et al. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient. J Hepatol, 2018, 68: 847-849.
[9] Chou SF, Tsai ML, Huang JY, et al. The Dual role of an ESCRT-0 component HGS in HBV transcription and naked capsid secretion. PLoS Pathog, 2015, 11: e1005123.
[10] Lam AM, Ren S, Espiritu C, et al. Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants. Antimicrob Agents Chemother, 2017, 61:e00680-17.
[11] Lu F, Wang J, Chen X, et al. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs. Front Med, 2017, 11: 502-508.
[12] Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016, 63: 261-283.
[13] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int, 2016, 10: 1-98.
[14] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67: 370-398.
[15] Butler EK, Gersch J, McNamara A, et al. Hepatitis B virus serum DNA and RNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection. Hepatology, 2018, 68: 2106-2117.
[16] Giersch K, Allweiss L, Volz T, et al. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol, 2017, 66: 460-462.
[17] Wang J, Du M, Huang H, et al. Reply to: "Serum HBV pgRNA as a clinical marker for cccDNA activity": Consistent loss of serum HBV RNA might predict the "para-functional cure" of chronic hepatitis B. J Hepatol, 2017, 66: 462-463.
[18] Tsuge M, Murakami E, Imamura M, et al. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol, 2013, 48: 1188-1204.
[19] Fan R, Zhou B, Xu M, et al. Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy. Clin Gastroenterol Hepatol, 2020, 18: 719-727 e717.
[20] Allweiss L, Lütgehetmann M, Volz T, et al. 42 pegylated-interferon-alpha alone or in combination with entecavir restores isg responsiveness and reduces intrahepatic viral loads and antigenemia in hepatitis b virus infected humanized mice. J Hepatol, 2012, 56: S18-S19.
[21] Wang J, Yu Y, Li G, et al. Natural history of serum HBV-RNA in chronic HBV infection. J Viral Hepat, 2018, 25: 1038-1047.
[22] Liu Y, Jiang M, Xue J, et al. Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection. BMC Gastroenterol, 2019, 19: 53.
[23] Lin N, Ye A, Lin J, et al. Diagnostic value of detection of pregenomic RNA in sera of hepatitis B virus-infected patients with different clinical outcomes. J Clin Microbiol, 2020, 58:e01275-19.
[24] van Bommel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology, 2015, 61: 66-76.
[25] Huang H, Wang J, Li W, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals. J Clin Virol, 2018, 99-100: 71-78.
[26] van Campenhout MJH, van Bommel F, Pfefferkorn M, et al. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. Hepatology, 2018, 68: 839-847.
[27] Liao H, Liu Y, Li X, et al. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy. Antivir Ther, 2019, 24: 105-115.
[28] Liu J, Li T, Zhang L, et al. The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among asian patients with chronic hepatitis B: a systematic review. Hepatology, 2019, 70: 1045-1055.
[29] Mak LY, Wong DK, Cheung KS, et al. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther, 2018, 47: 43-54.
[30] Chen EQ, Wang ML, Tao YC, et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA. J Viral Hepat, 2019, 26: 586-595.
[31] Jung KS, Park JY, Chon YE, et al. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol, 2016, 51: 830-839.
[32] Chi H, Li Z, Hansen BE, et al. Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy. Clin Gastroenterol Hepatol, 2019, 17: 182-191 e181. |
